Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Santhera: phase‑1 topline for AGAMREE® shows glucocorticoid activity without meaningful immunosuppression
Santhera reports topline results from a Phase‑1 study of AGAMREE® conducted by Catalyst, which show glucocorticoid and anti‑inflammatory effects at clinical doses but only minor immunosuppressive biomarker effects. Relevant immunosuppressive effects were observed only at doses above the currently approved AGAMREE dosage. Catalyst holds North American rights for DMD and potential follow‑on indications; Santhera retains pre‑negotiation rights outside North America and is entitled to sales‑based milestones and royalties. » Más en finanzen.net
Santhera reports 98% revenue growth in 2025 driven by AGAMREE
Santhera recorded a 98% increase in total revenue in 2025 to CHF 77.4 million, driven by strong uptake of AGAMREE in Europe and the US as well as license and milestone receipts. Product sales rose to CHF 25.8 million and license and milestone payments to CHF 23.1 million; Catalyst paid a milestone of USD 12.5 million after US sales exceeded USD 100 million. After year-end, Santhera signed an exclusive license agreement with Nxera worth up to USD 205 million, which included an upfront payment of USD 40 million. Cash and cash equivalents amounted to CHF 22.4 million as of 31.12.2025 (excluding the Nxera upfront), and the company expects cash-flow break-even in Q3 2026 without additional financing. » Más en finanzen.net
Santhera appoints Marc Clausse as chief commercial officer
Santhera Pharmaceuticals has appointed Marc Clausse as chief commercial officer (CCO). Clausse will assume responsibility for leading the company’s commercial activities. » Más en finanzen.net
Santhera closes $13m royalty agreement to support AGAMREE
Santhera has confirmed the closing of a $13 million royalty agreement announced in September with R-Bridge and the Partners Group. The agreement covers 25% of net royalties for AGAMREE from Catalyst in North America and from Sperogenix in China; payments are limited and will revert to Santhera after a cap or a set term is reached. Santhera retains a buyback right for the royalties and will use the funds to finance the global launch of AGAMREE. » Más en finanzen.net
Santhera: long-term analysis confirms improved safety profile of AGAMREE in Duchenne muscular dystrophy
Santhera reports positive topline results from a long-term analysis of the ongoing, open-label, multicenter GUARDIAN study of AGAMREE (vamorolone) in patients with Duchenne muscular dystrophy (DMD). The data confirm an improved safety profile for AGAMREE. Further details are set out in the full study. » Más en finanzen.net
Datos financieros
En el último trimestre, Santhera Pharma Aktie tuvo unos ingresos de 52,36 M € y un beneficio neto de -23,32 M €
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 52,36 M | - |
| Beneficio bruto | 19,44 M | - |
| Beneficio neto | -23,32 M | - |
| EBITDA | -4,16 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 215,78 M € |
Número de acciones | 15,31 M |
Máximo/mínimo de 52 semanas | 20,30 € - 12,69 € |
| Dividendos | No |
Beta | -0,28 |
Ratio P/E | -5,58 |
Ratio PEG | -0,07 |
Ratio P/B | -29,57 |
Ratio P/S | 1,92 |
Perfil de la empresa
Santhera Pharmaceuticals Holding AG, una empresa farmacéutica especializada, junto con sus filiales, desarrolla y comercializa medicamentos para enfermedades neuromusculares y pulmonares raras con una alta necesidad médica no cubierta en la Unión Europea y a nivel internacional. El candidato principal de la cartera de la compañía es vamorolona, que se está desarrollando como tratamiento para la distrofia muscular de Duchenne (DMD). Su cartera en fase clínica también incluye lonodelestat (POL6014) para tratar la fibrosis quística y otras enfermedades pulmonares neutrofílicas, así como omigapil, que trata las distrofias musculares congénitas. La compañía también concede en licencia a terceros los derechos fuera de Norteamérica y Francia sobre su producto aprobado, Raxone (idebenona), para el tratamiento de la neuropatía óptica hereditaria de Leber. Santhera Pharmaceuticals Holding AG se fundó en 2004 y tiene su sede en Pratteln, Suiza.
| Nombre | Santhera Pharma Aktie |
| CEO | Orlando Oliveira |
| Sede | Pratteln,
bl Suiza |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 06/03/2014 |
| Empleados | 78 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
SIX | SANN.SW |
London Stock Exchange | 0QN1.L |
Pnk | SPHDF |
London | 0QN1.L |